Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leonard Naymagon

Hematology New York, NY Medical Doctor

NPI 1952712234 CMS profile 7476533

10 E 102Nd St, New York, NY 10029

Open in the dashboard

General payments

$3,223

14 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leonard Naymagon of New York, NY is reported in the CMS Open Payments database as having received $3,223 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,960 2
2024 General $41 2
2023 General $26 1
2022 General $154 7
2021 General $43 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leonard Naymagon
  • Hematology median
  • Middle half of Hematology
  • National median

In program year 2025, general payments to Leonard Naymagon were reported at $2,960. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.

Show as a table
Year Leonard Naymagon Hematology median Middle half National median
2019 $0 $1,012 $122–$9,834 $163
2020 $0 $1,475 $115–$9,198 $114
2021 $43 $1,470 $125–$7,444 $132
2022 $154 $1,371 $139–$8,471 $149
2023 $26 $1,295 $147–$11,010 $160
2024 $41 $1,286 $146–$9,230 $164
2025 $2,960 $1,155 $135–$8,023 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sobi, Inc $2,365 3 payments
  2. Daiichi Sankyo Inc. $672 2 payments
  3. Novartis Pharmaceuticals Corporation $69 3 payments
  4. Shield Therapeutics Inc $41 2 payments
  5. Rigel Pharmaceuticals, Inc. $35 2 payments
  6. Amgen Inc. $21 1 payment
  7. Organon LLC $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $2,960 2 payments
  2. Food and Beverage $263 12 payments
Products named General payments · program years 2021–2025
  1. GAMIFANT $2,336 2 payments
  2. Vanflyta $650 1 payment
  3. PROMACTA Oncology $43 2 payments
  4. ACCRUFER $41 2 payments
  5. Tavalisse $35 2 payments
  6. Doptelet $29 1 payment
  7. PROMACTA Oncology $26 1 payment
  8. ENHERTU $22 1 payment
  9. Nplate $21 1 payment
  10. XGEVA $21 1 payment
  11. Other $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

701

Median for Hematology: 273

Drug cost

$1,416,894

Median for Hematology: $800,183

Branded share of claims

72.8%

Median for Hematology: 39.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doptelet Avatrombopag Maleate Brand 17 $354,566
Eliquis Apixaban Brand 300 $242,663
Tasigna Nilotinib Hcl Brand 12 $236,646
Calquence Acalabrutinib Maleate Brand 11 $170,704
Tavalisse Fostamatinib Disodium Brand 11 $164,033
Procrit Epoetin Alfa Brand 39 $88,070
Xarelto Rivaroxaban Brand 102 $80,661
Imatinib Mesylate Generic 39 $40,761
Retacrit Epoetin Alfa-Epbx Brand 18 $29,872
Fondaparinux Sodium Generic 15 $5,576

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 799 Part D prescribers listed as Hematology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$47,543

Medicare's payments for the services billed

Medicare patients

344

Average age 73

Services billed

567

197 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 43%
Diabetes 42%
Chronic kidney disease 41%
Heart failure 28%
Cancer 24%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record